Banco Santander S.A. Raises Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Banco Santander S.A. increased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating) by 6.1% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 15,280 shares of the medical research company’s stock after purchasing an additional 882 shares during the quarter. Banco Santander S.A.’s holdings in Thermo Fisher Scientific were worth $9,025,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently modified their holdings of TMO. Norges Bank purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at about $2,784,029,000. BlackRock Inc. increased its position in shares of Thermo Fisher Scientific by 3.8% in the fourth quarter. BlackRock Inc. now owns 30,982,611 shares of the medical research company’s stock valued at $20,672,838,000 after acquiring an additional 1,143,333 shares during the period. Marshall Wace LLP increased its position in shares of Thermo Fisher Scientific by 146.4% in the fourth quarter. Marshall Wace LLP now owns 1,043,844 shares of the medical research company’s stock valued at $696,497,000 after acquiring an additional 620,291 shares during the period. State Street Corp increased its position in shares of Thermo Fisher Scientific by 3.4% in the fourth quarter. State Street Corp now owns 16,223,173 shares of the medical research company’s stock valued at $10,828,875,000 after acquiring an additional 529,712 shares during the period. Finally, KBC Group NV boosted its stake in shares of Thermo Fisher Scientific by 52.9% during the 4th quarter. KBC Group NV now owns 697,313 shares of the medical research company’s stock valued at $465,276,000 after purchasing an additional 241,183 shares in the last quarter. Hedge funds and other institutional investors own 87.48% of the company’s stock.

Insider Activity

In other news, Director Jim P. Manzi sold 814 shares of the business’s stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $597.24, for a total transaction of $486,153.36. Following the completion of the transaction, the director now directly owns 15,807 shares of the company’s stock, valued at $9,440,572.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 2nd. The shares were sold at an average price of $588.36, for a total transaction of $5,883,600.00. Following the completion of the sale, the chief executive officer now directly owns 183,373 shares of the company’s stock, valued at $107,889,338.28. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Jim P. Manzi sold 814 shares of the company’s stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $597.24, for a total transaction of $486,153.36. Following the sale, the director now directly owns 15,807 shares of the company’s stock, valued at $9,440,572.68. The disclosure for this sale can be found here. Insiders sold 50,994 shares of company stock valued at $29,033,170 over the last three months. Insiders own 0.43% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on TMO shares. SVB Leerink lifted their target price on shares of Thermo Fisher Scientific from $630.00 to $650.00 and gave the company an “outperform” rating in a research note on Friday, July 29th. Morgan Stanley lifted their target price on shares of Thermo Fisher Scientific from $670.00 to $678.00 and gave the company an “overweight” rating in a research note on Friday, July 29th. Wells Fargo & Company lowered shares of Thermo Fisher Scientific from an “equal weight” rating to an “underweight” rating and cut their target price for the company from $605.00 to $525.00 in a research note on Monday, April 25th. Finally, Barclays lifted their target price on shares of Thermo Fisher Scientific from $630.00 to $685.00 and gave the company an “overweight” rating in a research note on Monday, August 1st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $661.08.

Thermo Fisher Scientific Stock Up 0.0 %

Shares of Thermo Fisher Scientific stock opened at $590.26 on Friday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.13 and a current ratio of 1.65. The stock has a market capitalization of $231.06 billion, a PE ratio of 31.41, a price-to-earnings-growth ratio of 1.84 and a beta of 0.83. Thermo Fisher Scientific Inc. has a 52-week low of $497.83 and a 52-week high of $672.34. The company has a 50-day simple moving average of $549.03 and a two-hundred day simple moving average of $557.79.

Thermo Fisher Scientific (NYSE:TMOGet Rating) last issued its earnings results on Thursday, July 28th. The medical research company reported $5.51 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.92 by $0.59. Thermo Fisher Scientific had a net margin of 17.37% and a return on equity of 24.36%. The business had revenue of $10.97 billion during the quarter, compared to analysts’ expectations of $9.95 billion. During the same period in the previous year, the company earned $5.60 earnings per share. The business’s revenue for the quarter was up 18.3% compared to the same quarter last year. On average, analysts anticipate that Thermo Fisher Scientific Inc. will post 22.92 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 14th. Stockholders of record on Thursday, September 15th will be issued a dividend of $0.30 per share. The ex-dividend date of this dividend is Wednesday, September 14th. This represents a $1.20 annualized dividend and a dividend yield of 0.20%. Thermo Fisher Scientific’s payout ratio is 6.39%.

Thermo Fisher Scientific Profile

(Get Rating)

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Featured Articles

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.